{
    "id": "8774eead-9146-4e07-acf7-4b6ab3bc1c22",
    "indications": {
        "text": "eszopiclone tablets indicated treatment insomnia . controlled outpatient sleep laboratory , eszopiclone tablets administered bedtime decreased sleep latency improved sleep maintenance . trials performed support efficacy 6 months duration . final formal assessments sleep latency maintenance performed 4 weeks 6-week study ( adults ) , end 2-week ( elderly ) end 6-month study ( adults ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lowest effective dose patient .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "eszopiclone tablets , usp , 2 mg round , white off-white , film-coated , identified debossed markings \u2018 383 \u2019 one side , \u2018 g \u2019 side supplied : ndc 68788-8077-3 bottle 30 tablets ndc 68788-8077-6 bottle 60 tablets ndc 68788-8077-9 bottle 90 tablets store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0f 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022 eszopiclone tablets contraindicated patients experienced complex sleep behaviors taking eszopiclone tablets [ ( 5.1 ) ] . \u2022eszopiclone tablets contraindicated patients known hypersensitivity eszopiclone . hypersensitivity include anaphylaxis angioedema [ ( 5.3 ) ] .",
    "ingredients": [
        {
            "name": "ESZOPICLONE",
            "code": "UZX80K71OE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53760"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        }
    ],
    "organization": "Preferred Pharmaceuticals Inc. USA",
    "name": "Eszopiclone",
    "effectiveTime": "20250502",
    "indications_original": "Eszopiclone tablets are indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance.\n                  The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only).",
    "contraindications_original": "Use the lowest effective dose for the patient.",
    "warningsAndPrecautions_original": "Eszopiclone Tablets, USP, 2 mg are round, white to off-white, film-coated, and identified with debossed markings of \u2018383\u2019 on one side, and \u2018G\u2019 on the other side and are supplied as: \n                  \n                     \n                        \u00a0NDC 68788-8077-3\tbottle of 30 tablets\n                     \n                        \u00a0NDC 68788-8077-6\tbottle of 60 tablets\n                     \n                        \u00a0NDC 68788-8077-9\tbottle of 90 tablets\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0F to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022\n                        Eszopiclone tablets are contraindicated in patients who have experienced complex sleep behaviors after taking eszopiclone tablets [see Warnings and Precautions (\n                        \n                        \n                           5.1\n                           )]\n                        \n                        . \n                     \n                     \n                        \u2022Eszopiclone tablets are contraindicated in patients with known hypersensitivity to eszopiclone. Hypersensitivity reactions include anaphylaxis and angioedema [see Warnings and Precautions (5.3)].",
    "drug": [
        {
            "name": "Eszopiclone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53760"
        }
    ]
}